#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections
Breakpoints19 Helmi 2021

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

  • Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
  • Watt M, et al. Infection. 2016;44(5):599-606.
  • Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
  • Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

  • Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
  • Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
  • Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

  • Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
  • Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

  • Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
  • Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
  • Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

  • Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
  • Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
  • Splinter et al. Ann Pharmacother. 2018;52:113-119.
  • Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
  • Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(134)

#134 – ESCMID Global Trials: PETER PEN and ASTARTE

#134 – ESCMID Global Trials: PETER PEN and ASTARTE

Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Tri...

8 Touko 1h 3min

#133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship

#133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship

Climate change in the context of healthcare can feel overwhelming but it doesn’t have to be paralyzing. We’re diving into the intersection of climate change and antimicrobial resistance with a focus o...

17 Huhti 48min

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

Episode Notes Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, ...

13 Maalis 1h 8min

#131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines

#131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines

In this third collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma ...

22 Helmi 1h

#130 – Dosing Consult: Amoxicillin

#130 – Dosing Consult: Amoxicillin

Drs. Ted Morton and Christine Lockowitz join Dr. Ryan Moenster to discuss all things amoxicillin, particularly in our pediatric patients. Our guests answer common questions, such as, what formulations...

30 Tammi 1h

#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci

#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci

We’re starting 2026 off with a BLAST as Dr. Gregory Eschenauer and Dr. George R Thompson make their Breakpoints debut to discuss Blastomyces, Histoplasma, Coccidioides, and Cryptococcus. They join hos...

16 Tammi 1h 22min

#128 – IDWeek 2025 Recap

#128 – IDWeek 2025 Recap

Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top late breaki...

19 Joulu 20251h 35min

#127 – What’s Pneu in Community-Acquired Pneumonia Part 2

#127 – What’s Pneu in Community-Acquired Pneumonia Part 2

As promised, our host Dr, Ryan Moenster is back and breaking down the recently published ATS pneumonia guidelines — what’s pneu, what’s controversial, and what it means for your antimicrobial game! Dr...

28 Marras 202552min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
adhd-podi
rss-rahamania
rss-liian-kuuma-peruna
rss-vapaudu-voimaasi
psykologia
rss-laadukasta-ensihoitoa
rss-narsisti
kesken
rss-valo-minussa-2
rss-arkea-ja-aurinkoa-podcast-espanjasta
rahapuhetta
rss-niinku-asia-on
rss-keskeneraiset-aidit
rss-naistalk
rss-duodecim-lehti
rss-tfa-8020-podcast
rss-luonnollinen-synnytys-podcast